Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Recurrence × Interleukin-2 × Clear all

Phase

Status

Completed 5 Terminated 4 Recruiting 2 Unknown 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 4 Uterine Cervical Neoplasms 2 Neuroblastoma 2 Nasopharyngeal Carcinoma 2 Lymphoma, Non-Hodgkin 2 Carcinoma, Non-Small-Cell Lung 2 Carcinoma, Hepatocellular 2 Breast Neoplasms 2 Stomach Neoplasms 1 Recurrence 1 Ovarian Neoplasms 1 Neoplasms 1 Lymphoma, T-Cell 1 Lymphoma, Large B-Cell, Diffuse 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hodgkin Disease 1 Head and Neck Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma 1 Anus Neoplasms 1 Advanced Refractory Solid Tumors 1 Advanced Malignant Solid Tumor 1

Interventions

Cyclophosphamide 16 fludarabine 12 Cisplatin 11 Rituximab 9 Dexamethasone 9 Gemcitabine 8 Cytarabine 7 fludarabine phosphate 6 Paclitaxel 6 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6 Lenalidomide 6 Decitabine 6 Radiotherapy 5 Etoposide 5 Carboplatin 5 Bendamustine Hydrochloride 5 camrelizumab 4 apatinib 4 Valproic Acid 4 Thalidomide 4 Procarbazine 4 Oxaliplatin 4 Injections 4 Bortezomib 4 Antilymphocyte Serum 4 tislelizumab 3 pomalidomide 3 Vinorelbine 3 Vinblastine 3 Radiosurgery 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05895370 2023-06-08

GI-HPVT-01

BGI, China

Phase 1 Unknown

Uterine Cervical Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡